Race, Geography Linked to Gaps in Prostate Cancer Care

Published Date: 15 Jul 2026

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

Read Full News

Latest News

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

FDA Approves Subcutaneous Isatuximab for MM Indications

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

AI-Driven Biomarker Predicts Prostate Cancer Outcomes

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Community Oncology Well Suited for Advanced Cancer Patients

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

Germline Variants Predict Lobular Breast Cancer Recurrence

For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.

Todays Updates

Thyroid: A Year in Review

Drs Kaniksha Desai and Anupam Kotwal discuss thyroid: a year in review.

Skip the TB Test? IPC/NPF Say Yes for Newer Biologics in Psoriasis

Deep Dive: The Evolving GLP-1 Class Overview

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Ensitrelvir Reduces COVID Risk Among Contacts Post-Exposure

Household contacts who initiate ensitrelvir vs placebo within 72 hours of symptom onset in the index patient have lower risk of developing COVID, with no apparent safety concerns.

How to Teach Professionalism? Ditch the Deficiency Focus

Teaching professionalism in medical school is required, but how best to do it? Move beyond a deficiency focus, experts say. Emphasize positive examples of professionalism.

Anemia Leads List of Factors That Affect BLVR Failure

Recognizing the impact of comorbidities may guide patient selection and improve outcomes.

Paid Parental Leave for Med School Faculty Often Lacking

Many medical schools don’t offer nationally recommended levels of paid parental leave.

Todays Updates

Thyroid: A Year in Review

Drs Kaniksha Desai and Anupam Kotwal discuss thyroid: a year in review.

Skip the TB Test? IPC/NPF Say Yes for Newer Biologics in Psoriasis

Deep Dive: The Evolving GLP-1 Class Overview

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Ensitrelvir Reduces COVID Risk Among Contacts Post-Exposure

Household contacts who initiate ensitrelvir vs placebo within 72 hours of symptom onset in the index patient have lower risk of developing COVID, with no apparent safety concerns.

How to Teach Professionalism? Ditch the Deficiency Focus

Teaching professionalism in medical school is required, but how best to do it? Move beyond a deficiency focus, experts say. Emphasize positive examples of professionalism.

Anemia Leads List of Factors That Affect BLVR Failure

Recognizing the impact of comorbidities may guide patient selection and improve outcomes.

Paid Parental Leave for Med School Faculty Often Lacking

Many medical schools don’t offer nationally recommended levels of paid parental leave.

Latest News

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.

News All Time

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

New Immune Therapy Boosts Disease Control in Prostate Cancer

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Multiple Myeloma Patients Have Unequal Access to Treatment

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

Is There a Role for Stimulants in Beating Cancer Fatigue?

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

Combination Treatment May Improve Multiple Myeloma Outcomes

Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.

Inside the Major Findings From the NHS-Galleri Trial

The largest randomized study of a multicancer blood test found no reduction in late-stage cancers, while raising new questions about stage shift, mortality benefit, and population screening.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

Pain that interferes with daily functioning is associated with higher odds of frailty and its progression in adult survivors of childhood cancer.

The Growing Role of AI in Cancer Treatment

Cancer care is becoming too complex for any one clinician to track alone, making AI an increasingly valuable tool in modern oncology.

Capivasertib Wins Metastatic Prostate Cancer Approval

The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.

PSA Screening May Modestly Curb Prostate Cancer Deaths

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Simpler Screening Criteria Could Catch More Lung Cancers

A study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.

Recommended News For You

FDA Approves Sickle Cell Gene Therapy for Young Kids

Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances

New BiTE Agent for Small Cell Lung Cancer Approved by the FDA.

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

New Standard for Newly Diagnosed Pediatric B-Cell Acute Lymphoblastic Leukemia

Recommended Articles For You

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection 

Oncology Drug Trends 2025: FDA Approvals, Immuno-Oncology, and Clinical Trial Insights 

HSC Failure in Fanconi Anemia: Mechanisms, Models, and Emerging Therapeutic Pathways 

The Benefits and Risks of Transurethral Resection of Bladder Tumor  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

combating racial discrimination in next-generation breast cancer screening.

2.

Year in Review: Chronic Lymphocytic Leukemia

3.

An ancient signaling pathway and 20 years of research offer hope for rare cancer

4.

J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79

5.

New imaging technique identifies glioblastoma patients who would benefit from immunotherapy

1.

Introduction to Immune Thrombocytopenic Purpura

2.

Tumor Evolution Forecasting for Precision Oncology Decisions

3.

Decoding the Failures in Acute Myeloid Leukemia Treatment: Mechanisms, Pathways, & Survival Outcomes

4.

How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?

5.

Hope for a Cure: Exploring New Treatments for Sickle Cell Anemia

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

A New Era in Managing Cancer-Associated Thrombosis

2.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

3.

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

4.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot